Study examines immunotherapy and cerebrospinal fluid biomarkers in patients with Alzheimer's disease
Immunotherapy with the antibody bapineuzumab in patients with mild to moderate Alzheimer disease resulted in decreases in a cerebrospinal fluid biomarker, which may indicate downstream effects on the degenerative process, according to a report published Online First by Archives of Neurology.
Alzheimer disease (AD) is a progressive neurodegenerative disease characterized by, among other things, deposits of extracellular β-amyloid (Αβ) plaques and intraneuronal neurofibrillary tangles with accompanying decreases in cerebrospinal fluid (CSF) Αβ and increases in CSF tau proteins. Bapineuzumab is an anti-Αβ monoclonal antibody, and immunotherapy with antibodies against Αβ is one of the major disease-modifying therapeutic approaches being evaluated for AD, the authors write in their study background.
Kaj Blennow, M.D., Ph.D., of the University of Gothenburg, Sweden, and colleagues conducted a combined analysis of two double-blind, placebo-controlled trials that included 46 patients with mild to moderate AD. A total of 27 patients were treated with bapineuzumab and 19 with placebo. The researchers evaluated whether bapineuzumab affected the CSF levels of the downstream biomarkers, total tau (T-tau) and phosphorylated tau (P-tau), and the primary biomarker Αβ in the completed trials.
"The reduction in the downstream biomarker CSF P-tau following treatment with bapineuzumab suggests that bapineuzumab reduces brain levels of P-tau, which may also reduce the formation of tangles in the brain," the authors note.
Although there was a reduction in CSF T-tau, it did not reach statistical significance compared with placebo. No clear-cut differences were observed for CSF Αβ, the study results indicate. But the observed decrease in both P-tau and T-tau require further examination, the authors note.
"An important question remains whether such changes in CSF biomarkers correlate with clinical benefit. This question will be addressed in the ongoing bapineuzumab phase 3 trials," the authors conclude.
More information: Arch Neurol. Published online April 2, 2012. doi:10.1001/archneurol.2012.90
Provided by JAMA and Archives Journals
- Clinical trial examines antioxidant effects for Alzheimer's disease on cerebrospinal fluid biomarkers Mar 19, 2012 | not rated yet | 0
- Changes seen in cerebrospinal fluid levels before onset of Alzheimer dementia Jan 02, 2012 | not rated yet | 0
- Neuroimaging technique shows potential of bapineuzumab treatment and might be useful in assessing other drugs for Alzhei Feb 28, 2010 | not rated yet | 0
- Biomarkers may help predict risk of Alzheimer's disease in patients with mild cognitive impairment Jul 21, 2009 | not rated yet | 0
- Compounds in spinal fluid associated with faster decline among individuals with mild dementia May 11, 2009 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Force Between Two Concentric Solenoids
3 hours ago Imagine a finite length solenoid with outer radius R1 and inner radius R2. This solenoid has a time-varying current going though it. This solenoid is...
Synchrotron, question about insertion devices and electron velocity
3 hours ago When an electron enters an insertion device (wiggler and undulator) from the storage ring in a synchrotron the tangential velocity is equal to the...
Equating differentials => equating coefficients
5 hours ago Hi all, In thermodynamics one often has equations like A dx + B dy = ∂f/∂x dx + ∂f/∂y dy From which follows A = ∂f/∂x B = ∂f/∂y
The idea behind a reverse shock
10 hours ago So in a supernova explosion for example (5th slide) http://www.astro.princeton.edu/~burrows/classes/541/blastwavesChisari.pdf Ambient medium is...
Guass's Law for a charge distribution
10 hours ago First, this is not a homework question, just something I've been confused about for some time. I understand how to use Guass's law in many ways but...
11 hours ago Hello :) i'm new to this forum, so excuse me for my straightforwardness ;) I'm working on my bachelor work and i can't find a solution. I'm writing...
- More from Physics Forums - Classical Physics
More news stories
In the search for medication against Alzheimer's disease, scientists have focused – among other factors – on drugs that can break down Amyloid beta (A-beta). After all, it is the accumulation of A-beta that causes the ...
Alzheimer's disease & dementia May 24, 2013 | not rated yet | 0
(Medical Xpress)—The way Alzheimer's disease is portrayed by advocacy groups and the media is having undue influence on the euthanasia debate, according to a Deakin University nursing ethics professor.
Alzheimer's disease & dementia May 24, 2013 | not rated yet | 2
Cinnamon: Can the red-brown spice with the unmistakable fragrance and variety of uses offer an important benefit? The common baking spice might hold the key to delaying the onset of –– or warding off ...
Alzheimer's disease & dementia May 23, 2013 | 5 / 5 (5) | 0 |
An anti-cancer drug reverses memory deficits in an Alzheimer's disease mouse model, University of Pittsburgh Graduate School of Public Health researchers confirm in the journal Science.
Alzheimer's disease & dementia May 23, 2013 | not rated yet | 0 |
Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.
Alzheimer's disease & dementia May 23, 2013 | 3 / 5 (2) | 3 |
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
16 hours ago | 5 / 5 (3) | 5
(HealthDay)—Animals make great companions for senior citizens, but elderly people who always drive with a pet in the car are far more likely to crash than those who never drive with a pet, researchers have ...
8 hours ago | not rated yet | 1
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
16 hours ago | not rated yet | 1
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
16 hours ago | not rated yet | 0
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
16 hours ago | not rated yet | 0